A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC
A Pilot Study of MPDL3280A (PD-L1) Antibody Therapy and Hypofractionated Image-guided Radiotherapy (HIGRT) in Patients With Metastatic Non-Small Cell Lung Cancer
Sponsor: University of Michigan Rogel Cancer Center
A EARLY_PHASE1 clinical study on Non-small Cell Lung Cancer, this trial is completed. The trial is conducted by University of Michigan Rogel Cancer Center and has accumulated 9 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed EARLY_PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed EARLY_PHASE1
-
Mar 2019 — Jan 2021 [monthly]
Completed EARLY_PHASE1
Status: Active Not Recruiting → Completed
-
Feb 2019 — Mar 2019 [monthly]
Active Not Recruiting EARLY_PHASE1
▶ Show 4 earlier versions
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting EARLY_PHASE1
-
Apr 2017 — Jun 2018 [monthly]
Active Not Recruiting EARLY_PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Apr 2017 [monthly]
Recruiting EARLY_PHASE1
Phase: Phase 0 → EARLY_PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting Phase 0
First recorded
Oct 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Michigan Rogel Cancer Center
- University of Washington
For direct contact, visit the study record on ClinicalTrials.gov .